Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BTI 320

Next Previous
X
Search
Drug Profile

BTI 320

Alternative Names: BTI-320; PAZ-320

Latest Information Update: 17 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boston Therapeutics
  • Developer Nanomix Corporation
  • Class Antihyperglycaemics; Mannans
  • Mechanism of Action Alpha-glucosidase inhibitors; Amylase inhibitors; Carbohydrate metabolism inhibitors; Glucose modulators; Hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 29 Sep 2020 Boston Therapeutics withdraws its phase II trial in Type 2 diabetes mellitus (Adults, In elderly, Treatment experienced) in France (NCT04569214)
  • 22 Oct 2018 No development reported - Phase-II for Type-2 diabetes mellitus in Hong Kong (PO)
  • 31 Aug 2018 Boston Therapeutics plans a phase I/II trial for Type II Diabetes Mellitus in USA (NCT03655535)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top